Timing of elevations of autoantibody isotypes in rheumatoid arthritis prior to disease diagnosis.
To evaluate patterns of elevations of isotypes of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) pre- and post-rheumatoid arthritis (RA) diagnosis. Using the Department of Defense Serum Repository we identified 214 RA cases and 210 matched controls. A mean of 3 pre-RA and 1 post-RA diagnosis serum samples were tested for RF and ACPA immunoglobulin (Ig) A, IgG, and IgM. The timing and trajectories of elevations of autoantibodies were evaluated. Pre-RA autoantibody levels were elevated in cases vs. controls as follows: ACPA-IgG 17.9 years, RF-IgA 14.2 years, RF-IgM 7.2 years, ACPA-IgA 6.2 years and ACPA-IgM and RF-IgA both at 5.0 years (p<0.01, all comparisons). The autoantibodies as positive/negative showed similar relationships, with the median time of first positivity of ACPA-IgG at 1.9 years pre-RA, RF-IgA at 1.7 years, followed by the other isotypes. Only ACPA-IgA positivity significantly increased post-RA (19% 0-2 years pre-RA vs. 39% >2 years post-RA, p=0.04). All autoantibody levels demonstrated an early initial elevation, a period of stability, then an increase immediately Pre-RA diagnosis. A pre-RA endotype of early elevation of autoantibodies was associated with increased use of biologic therapy, and a higher prevalence of sicca symptoms and lung disease post-RA. Differences in patterns of elevations of autoantibody isotypes have implications in understanding the pathophysiology of RA development. These include understanding what factors drive initial autoantibody elevations compared to what factors (including mucosal) drive later increases in autoantibodies and a transition to clinically-apparent RA, and how pre-RA endotypes may influence post-RA phenotypes. This article is protected by copyright. All rights reserved.